UGT1A1*28 POLYMORPHISM AND VOMITING IN ADVANCED COLORECTAL CANCER

被引：0
|
作者：
El Bastawisy, A. E. [1 ]
Farid, S. F. [2 ]
Bahnasy, A. A. [1 ]
El Zeiny, A. M. [1 ]
机构：
[1] Cairo Univ, Natl Canc Inst, Med Oncol Dep, Giza, Egypt
[2] Cairo Univ, Fac Pharm, Giza, Egypt
来源：
ANNALS OF ONCOLOGY | 2013年 / 24卷
关键词：
D O I：
10.1093/annonc/mdt459.153
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] UGT1A1*28 polymorphism and vomiting in advanced colorectal cancer.
    El Bastawisy, Ahmed El Saied
    El-Zeiny, Amany
    Farid, Samar
    Bahnasy, Abeer
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] UGT1A1*28 polymorphism in advanced colorectal cancer: The story is not yet ended.
    El Bastawisy, Ahmed El Saied
    El-Zeiny, Amany
    Farid, Samar
    Bahnasy, Abeer
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [3] UGT1A1*28 polymorphism in ovarian cancer patients
    Cecchin, E
    Russo, A
    Corona, G
    Campagnutta, E
    Martella, L
    Boiocchi, M
    Toffoli, G
    ONCOLOGY REPORTS, 2004, 12 (02) : 457 - 462
  • [4] The role of UGT1A1*28 polymorphism in the pharmacodynarnics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
    Toffoli, Giuseppe
    Cecchin, Erika
    Corona, Giuseppe
    Russo, Antonio
    Buonadonna, Angela
    D'Andrea, Mario
    Pasetto, Lara Maria
    Pessa, Sergio
    Errante, Domenico
    De Pangher, Vincenzo
    Giusto, Mauro
    Medici, Michele
    Gaion, Fernando
    Sandri, Paolo
    Galligioni, Enzo
    Bonura, Salvatore
    Boccalon, Massimo
    Biason, Paola
    Frustaci, Sergio
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) : 3061 - 3068
  • [5] Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer
    Bajro, Marija Hiljadnikova
    Josifovski, Toni
    Panovski, Milco
    Jankulovski, Nikola
    Nestorovska, Aleksandra Kapedanovska
    Matevska, Nadica
    Petrusevska, Natalija
    Dimovski, Aleksandar J.
    CANCER GENETICS, 2012, 205 (04) : 163 - 167
  • [6] Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism
    Hazama, Shoichi
    Nagashima, Atsushi
    Kondo, Hiroshi
    Yoshida, Shin
    Shimizu, Ryoichi
    Araki, Atsuhiro
    Yoshino, Shigefumi
    Okayama, Naoko
    Hinoda, Yuji
    Oka, Masaaki
    CANCER SCIENCE, 2010, 101 (03) : 722 - 727
  • [7] UGT1A1*28 polymorphism influences glucuronidation of bazedoxifene
    Lusin, T. Trdan
    Mrhar, A.
    Trontelj, J.
    PHARMAZIE, 2015, 70 (02): : 94 - 96
  • [8] Meta-analysis revisiting the influence of UGT1A1*28 and UGT1A1*6 on irinotecan safety in colorectal cancer patients
    Thu Nguyen, Cuc Thi
    Minh Thuy, Nguyen Thi
    Huong, Phung Thanh
    PHARMACOGENOMICS, 2024, 25 (10-11) : 469 - 477
  • [9] A study of the association between UGT1A1*28 variant allele of UGT1A1 gene and colonic phenotype of sporadic colorectal cancer
    Anon, Benjamin
    Perray, Clemence
    Regnault, David
    Caulet, Morgane
    Orain, Isabelle
    Godart, Bruno
    Pages, Jean-Christophe
    Tallet, Anne
    Ouaissi, Mehdi
    Guyetant, Serge
    Barin-le Guellec, Chantal
    Lecomte, Thierry
    DIGESTIVE AND LIVER DISEASE, 2019, 51 (04) : 579 - 583
  • [10] Clinical Implications of UGT1A1*28 Genotype Testing in Colorectal Cancer Patients
    Shulman, Katerina
    Cohen, Ilana
    Barnett-Griness, Ofra
    Kuten, Abraham
    Gruber, Stephen B.
    Lejbkowicz, Flavio
    Rennert, Gad
    CANCER, 2011, 117 (14) : 3156 - 3162
12345